GU Cancers 2024 | The emerging role of PET tracers in managing renal cell carcinoma

Michael Hofman, FRACP, MBBS, Peter MacCallum Cancer Centre, Melbourne, Australia, comments on advances in positron emission tomography (PET) tracers for renal cell carcinoma (RCC). PSMA, which has been predominantly used in prostate cancer, has also shown to be a promising agent in RCC. Fibroblast activation protein (FAP) inhibitor (FAPI) PET/CT imaging has additionally shown encouraging results in RCC and Dr Hofman additionally highlights the Phase III ZIRCON trial (NCT03849118) of a zircon-labelled antibody. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.